中性粒细胞明胶酶相关脂质运载蛋白在慢性阻塞性肺疾病急性加重期的表达

摘要

目的 观察中性粒细胞明胶酶相关脂质运载蛋白(NGAL)在慢性阻塞性肺疾病急性加重期患者中的表达和意义.方法 随机选取慢阻肺疾病急性加重(AECOPD)患者40例、对照组25例.应用酶联免疫吸附法(ELISA)测定AECOPD患者治疗前、后及对照组的血NGAL水平.结果 AECOPD患者治疗前后及对照组血NGAL浓度分别为(112.18±20.96)μg/L、(79.02±15.39)μg/L、(64.74±13.20)μg/L,3组间差异具有统计学意义(P<0.05),其中频繁加重患者血NGAL高于一般患者.AECOPD患者治疗前血NGAL与CRP、中性粒细胞百分比、住院天数呈正相关,与肺功能受损程度(FEV1占预计值百分比)呈负相关.结论AECOPD患者血NGAL在治疗后显著降低,NGAL可作为评估AECOPD患者病情严重程度的指标.%Objective To observe the expression of neutrophil gelatinase-associated lipocalin ( NGAL ) in AECOPD patients, and to analyze the relationship of NGAL and AECOPD. Methods 40 patients with AECOPD and 25 healthy controls were recruited into the study. The plasma NGAL of both pretherapy and post-treatment of AECO-PD patients and controls ' plasma NGAL were measured by ELISA. Results In AECOPD patients, the plasma concentrations of NGAL of pretherapy and post-treatment were ( 112. 18 ± 20. 96 ) μg/L, ( 79. 02 ± 15. 39 ) μg/L, and (64. 74 ± 13. 20) μg/L. The NGAL levels of AECOPD patients frequently were significantly higher than the pa-tients with AECOPD annually. Before treatment, the levels of NGAL were positively correlated with CRP, neutrophil cell count and hospitalization time, and negatively correlated with severity of pulmonary function. Conclusion The plasma NGAL of AECOPD decreases after treatment, and it could be a biomarker to evaluate the severity of AECOPD.